Trabectedin plus Durvalumab in Patients with Advanced Pretreated Soft Tissue Sarcoma and Ovarian Carcinoma (TRAMUNE): An Open-Label, Multicenter Phase Ib Study.
Maud ToulmondeMehdi BrahmiAntoine GiraudCamille ChakibaAlban BessedeMichèle KindEmilie ToulzaMarina PulidoSabrina AlbertJean-Philippe GuéganSophie CousinSimone Mathoulin-PelissierRaul E PerretSabrina CroceJean Yves BlayIsabelle L Ray-CoquardAnne FloquetAntoine ItalianoPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Combining trabectedin and durvalumab is manageable. Promising activity is observed in patients with platinum-refractory ovarian carcinoma. See related commentary by Digklia et al., p. 1745.
Keyphrases